Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in Early-Stage Hodgkin Lymphoma
A phase 2 trial found that brentuximab vedotin and nivolumab added to limited chemotherapy produced a 92 percent complete response ...
A phase 2 trial found that brentuximab vedotin and nivolumab added to limited chemotherapy produced a 92 percent complete response ...
A phase 2a trial found that surufatinib combined with PD-1/PD-L1 inhibitors as first-line maintenance therapy yielded a median progression-free survival ...
A phase 2 dose-finding trial found that a single oral dose of the netupitant-palonosetron combination NEPA effectively prevented chemotherapy-induced nausea ...
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine